top headlines
With 89% of AI pilots failing to scale, biopharmas can [...]
EPIK Biosciences launches with ketamine pipeline targeting mental health, chronic pain and addiction
EPIK Biosciences has launched as a new psychedelic drug development [...]
related posts
Movers & Shakers
sponsored content
With 89% of AI pilots failing to scale, biopharmas can [...]
Interview with Carol Grassi Mircich, chief commercial marketing and innovation [...]
As Rare Disease Day 2026 highlights the challenges faced by [...]
Other news
Remepy has announced a collaboration with Merck KGaA, Darmstadt Germany, [...]
RxLogix has launched a new version of its PVOne.AI platform [...]
Myomaker Bio, a UK biotechnology company spun out from Loughborough [...]
Abivax will present nine scientific abstracts on obefazimod at Digestive [...]
Viz.ai has entered a collaboration with Johnson & Johnson to [...]
Veristat has agreed to acquire Certara’s regulatory and medical writing [...]
